This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DLAT · Western blot design guide
DLAT Western Blot Planning Guide
Plan a DLAT Western blot around the catalog-observed 69 kDa band, image-backed A04469-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
DLAT Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 69 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Kidney | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 69 kDa |
| ⓘ | Localization | Mitochondrion matrix |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated DLAT Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bronchus |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A04469-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected DLAT Western Blot Band Size?
Use the product-observed 69 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 69 kDa | Matches the authoritative product WB observation. |
| 69 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected DLAT appearancePlan around 69 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 69 kDa; use this as the primary experimental expectation. |
| Calculated mass | 69 kDa from UniProt P10515; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A04469-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 69 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing DLAT band
A04469-2 · DLAT
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for DLAT Western blot
🧪Use Kidney as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Kidney (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for DLAT
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | High | Protein (HPA) | HPA → |
| Hippocampus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced DLAT Western Blot Tips
Deeper troubleshooting and optimisation questions for DLAT, answered from its protein features.
Which band should guide the blot?
Use 69 kDa, the observation attached to the authoritative A04469-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 69 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for DLAT Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A04469-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
DLAT Western Blot Reagents
Human/Mouse/Rat-reactive DLAT Western blot reagents with authoritative product imagery.
Real WB data
Anti-DLAT Antibody Picoband®
Cat # A04469-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P10515
- Human Protein Atlas — DLAT
- A04469-2 product record
- PMC12087083 — Tetrathiomolybdate alleviates bleomycin-induced pulmonary fibrosis by reducing copper concentration and suppressing EMT (European journal of medical research, 2025)
- PMC13131405 — Cuproptosis in atrazine-induced hepatotoxicity: ATOX1 as a therapeutic target for lycopene-mediated protection (Journal of advanced research, 2026)
- PMC12151749 — Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis (Cancer cell, 2025)